Aptevo Therapeutics (APVO) EBIAT (2016 - 2025)
Aptevo Therapeutics' EBIAT history spans 11 years, with the latest figure at -$7.5 million for Q3 2025.
- For Q3 2025, EBIAT fell 47.99% year-over-year to -$7.5 million; the TTM value through Sep 2025 reached -$26.5 million, down 6.07%, while the annual FY2024 figure was -$24.1 million, 29.38% down from the prior year.
- EBIAT for Q3 2025 was -$7.5 million at Aptevo Therapeutics, down from -$6.2 million in the prior quarter.
- Across five years, EBIAT topped out at $28.0 million in Q2 2022 and bottomed at -$8.1 million in Q3 2022.
- The 5-year median for EBIAT is -$6.4 million (2025), against an average of -$4.4 million.
- The largest annual shift saw EBIAT tumbled 350.47% in 2021 before it surged 453.13% in 2022.
- A 5-year view of EBIAT shows it stood at -$6.3 million in 2021, then rose by 17.68% to -$5.2 million in 2022, then crashed by 38.31% to -$7.1 million in 2023, then grew by 11.61% to -$6.3 million in 2024, then decreased by 19.6% to -$7.5 million in 2025.
- Per Business Quant, the three most recent readings for APVO's EBIAT are -$7.5 million (Q3 2025), -$6.2 million (Q2 2025), and -$6.4 million (Q1 2025).